Study shows that there is slower cancer drug approval in Europe

The EMA perspective on drug approval process in the era of precision medicineПодробнее

Timely and efficient anti-cancer treatment for everybody: dream or reality in Europe? ESMO SurveyПодробнее

The European Medicines Agency and patient involvement in the drug approval processПодробнее

Huge inequalities in healthcare. Making sure that Europe's 'Beating Cancer Plan' works for patientsПодробнее

The future of European research and its impact on cancer inequalitiesПодробнее

Better screening, research and treatment: the EU is on a mission to beat cancerПодробнее

The new cancer drugs - Helpful or harmful? | DW DocumentaryПодробнее

Learn about tolvaptanПодробнее

EMA 25th Anniversary Symposium New Approaches in Patient Focused Cancer DrugПодробнее

PD 01 - Europe’s Beating Cancer Plan: Catalyzing Research and Innovation for Better OutcomesПодробнее

Learn about Europe's Beating Cancer Plan: Early Detection and High-Quality TreatmentПодробнее

Harvard-MIT Center for Reg. Science Lecture (4-4-23) - Dubious FDA drug ApprovalsПодробнее

Stopping Drug Resistance in Its Tracks | The EU's Global RoleПодробнее

Policy Dialogue | The Revision of the EU Regulations on Medicines for Children and Rare DiseasesПодробнее

European Drug Report 2021: highlightsПодробнее

Discover the Cancer Mission – Join the European Research and Innovation Days 2022Подробнее

Marketing Authorization Application Accepted by European Medicines Agency for ZolbetuximabПодробнее

European Drug Report 2018: highlightsПодробнее

Beating Cancer: The EU Cancer Plan ExplainedПодробнее